Navigation Links
Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007

by other companies. We have described the reconciliations of each of our non-GAAP financial measures above to the most directly comparable GAAP financial measures.

Management uses our non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes because we believe such measures are one important indicator of the strength and the performance of our business because they provide a link to operating cash flow. We also believe that analysts and investors use such measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

Three Months Ended Nine Months Ended

December 31, December 31,

2007 2006 2007 2006

Gross Profit

GAAP gross profit $2,939,359 $1,406,092 $7,664,323 $3,922,700

% of sales 79% 65% 79% 69%

SFAS 123 (R) stock

option charges 9,008 - 18,695 1,361

Depreciation expenses 13,277 12,330 41,882 36,358

Non-GAAP gross

profit 2,961,644 1,418,422 7,724,900 3,960,419

Operating Expenses

GAAP operating

expenses 3,868,656 $2,459,060 $10,787,959 $8,040,105

SFAS 123 (R) stock

option charges 187,438 158,770 848,394 634,585


expenses 43,842 37,015 122,001 108,367


expenses 209,862 25,210 632,865 78,323

Non-GAAP operating

expenses 3,427,514 2,238,065 9,184,699 7,218,830

Operating Loss

GAAP operating


SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Uroplasty to Host Third Quarter Conference Call on February 11
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
(Date:8/20/2014)... SAN JOSE, Calif. , Aug. 20, 2014 ... UCSD highlights the transformative collaboration between the school,s ... (IoT).  As part of the Intel® Software Academic ... between computer sciences and the human body.  ... The study exhibits the work of ...
(Date:8/20/2014)... Cranford, NJ (PRWEB) August 20, 2014 ... solutions, announced today that it has expanded its myPROpad™ ... of the EQ-5D-5L, one of the most widely ... for measuring general health status. The EQ-5D is used ... to generate a measure that can be used to ...
(Date:8/19/2014)... 2014 One of the major ... an inadequate vascular supply. Nutrient and gas transport ... is critical for successful regeneration and integration into ... deficiencies in vascularization and promote angiogenesis in a ... scaffold design and architecture, and enhancing scaffolds with ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2EQ-5D™ Assessment Now Available for iPad 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... deCODE genetics,(Nasdaq: DCGN ) today ... laboratory, which processes the company,s deCODEme(TM) personal,genome ... several common,diseases, has been accredited by the ... inspection. The U.S. Centers for Medicare and ...
... to Launch into High Growth Brazilian Market for ... Aesthera announced today the receipt of ANVISA clearance ... platforms in Brazil. ANVISA (Agencia Nacional de ... and regulatory agency charged with clearing all applications ...
... in Groton , Connecticut MORRISVILLE, ... contract manufacturer of APIs, intermediates and Drug Products to the ... pleased to announce the recent award by Pfizer Inc. as ... at Pfizer,s Groton, Connecticut R&D center on May 1, 2009. ...
Cached Biology Technology:deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 2deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 3deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 4Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 2Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 3Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem 2
(Date:8/20/2014)... -  Issue Serious allergic reactions to ... threatening for some children.    What you should ... food allergies and this number may be increasing, especially among ... to have food allergies.  The symptoms of ... to breathing difficulties and loss of consciousness. Symptoms can also ...
(Date:8/20/2014)... outcomes of approximately 3 million infants, a team of ... University of Massachusetts Medical School, have shown that newborn ... implemented across public health newborn screening programs. Data from ... issue of the Journal of the American Medical ... SCID in newborns is higher than previously thought and ...
(Date:8/20/2014)... UK scientists have discovered that acral melanomas the rare ... death are genetically distinct from other more common types ... published in the journal Pigment Cell & Melanoma Research ... the hands, soles of the feet, nail-beds and other hairless ... melanoma, it,s not caused by UV damage from the sun. ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... are urgently needed in resource-limited countries. A ... Microbiology colloquium, "Bringing the Lab to the Patient: ... the challenges inherent in bringing new medical devices ... where they are needed most. Point-of-care diagnostics (POCTs) ...
... helped open a new door of possibility in the high-stakes ... an international team, the scientists including Stanford Woods Institute ... found a way to create future ocean conditions in a ... the device can mimic the composition of the future ocean ...
... world dolomite is quite common. More than 90 percent of ... first described scientifically in the 18th century. But who would ... not fully understood, although geologists are aware of large deposits ... years. The process of recent primary dolomite formation is restricted ...
Cached Biology News:Report addresses challenges in implementing new diagnostic tests where they are needed most 2Stanford researchers help predict the oceans of the future with a mini-lab 2How does dolomite form? 2
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
DL-Dithiothreitol (Clelands Reagent) ,PROTEASE FREE!! ,Molecular Biology Grade ,PRODUCT MUST SHIP NEXT DAY DURING HOT SUMMER MONTHS. ,C 4 H 10 O 2 S 2 ,Molecular Weight: 154.25 ,CAS RN: [27565-...
DTT 50 l...
Biology Products: